Apoptosome-dependent caspase activation proteins as prognostic markers in Stage II and III colorectal cancer

British Journal of Cancer

Volumn 106, Issue 9, 2012, Pages 1499-1505

  Hector, S ^a,b   Conlon, S ^c   Schmid, J ^a,b   Dicker, P ^d   Cummins, R J ^c   Concannon, C G ^a,b   Johnston, P G ^e   Kay, E W ^c   Prehn, J H M ^a,b  

^a Department of Physiology and Medical Physics ^*  (Ireland)

^b Centre for Systems Medicine   (Ireland)

^c BEAUMONT HOSPITAL   (Ireland)

^d ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

^e QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

Apoptosis; caspases; colorectal cancer; prognosis

Indexed keywords

APOPTOSOME; APOPTOSOME DEPENDENT CASPASE ACTIVATION PROTEIN; APOPTOTIC PROTEASE ACTIVATING FACTOR 1; CASPASE; FLUOROURACIL; FOLINIC ACID; PROCASPASE 3; PROCASPASE 9; SECOND MITOCHONDRIAL ACTIVATOR OF CASPASE; TUMOR MARKER; UNCLASSIFIED DRUG; X LINKED INHIBITOR OF APOPTOSIS;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; COLORECTAL CANCER; DISEASE FREE SURVIVAL; ENZYME ACTIVATION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; APOPTOSOMES; CASPASES; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS, PHASE III AS TOPIC; COLORECTAL NEOPLASMS; ENZYME ACTIVATION; FEMALE; FLUOROURACIL; HUMANS; IMMUNOENZYME TECHNIQUES; LEUCOVORIN; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; TISSUE ARRAY ANALYSIS;

EID: 84860255669     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2012.133     Document Type: Article

References (40)

1. Arango D, Wilson AJ, Shi Q, Corner GA, Aranes MJ, Nicholas C, Lesser M, Mariadason JM, Augenlicht LH (2004) Molecular mechanisms of action and prediction of response to oxaliplatin in colorectal cancer cells Br J Cancer 91(11): 1931-1946 (Pubitemid 40065523)
2. Bedi A, Pasricha PJ, Akhtar AJ, Barber JP, Bedi GC, Giardiello FM, Zehnbauer BA, Hamilton SR, Jones RJ (1995) Inhibition of Apoptosis during Development of Colorectal Cancer. Cancer Res 55(9): 1811-1816
3. Center MM, Jemal A, Smith RA, Ward E (2009) Worldwide variations in colorectal cancer. CA Cancer J Clin 59(6): 366-378
4. Christoph F, Weikert S, Kempkensteffen C, Krause H, Schostak M, Köllermann J, Miller K, Schrader M (2006a) Promoter hypermethylation profile of kidney cancer with new proapoptotic p53 target genes and clinical implications. Clin Can Res 12(17): 5040-5046 (Pubitemid 44453329)
5. Christoph F, Weikert S, Kempkensteffen C, Krause H, Schostak M, Miller K, Schrader M (2006b) Regularly methylated novel pro-apoptotic genes associated with recurrence in transitional cell carcinoma of the bladder. Int J Cancer 119(6): 1396-1402 (Pubitemid 44258817)
6. de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, Boni C, Cortes-Funes H, Cervantes A, Freyer G, Papamichael D, Le Bail N, Louvet C, Hendler D, de Braud F, Wilson C, Morvan F, Bonetti A (2000) Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18(16): 2938-2947 (Pubitemid 30644117)
7. De Oliveira Lima F, De Oliveira Costa H, Barrezueta LF, Fujiyama Oshima CT, Silva Jr. JA, Gomes TS, Pinheiro Jr. N, Neto RA, Franco M (2009) Immunoexpression of inhibitors of apoptosis proteins and their antagonist SMAC/DIABLO in colorectal carcinoma: correlation with apoptotic index, cellular proliferation and prognosis. Oncol Rep 22(2): 295-303
8. Deveraux QL, Reed JC (1999) IAP family proteins-suppressors of apoptosis. Genes Dev 13(3): 239-252
9. Endo K, Kohnoe S, Watanabe A, Tashiro H, Sakata H, Morita M, Kakeji Y, Maehara Y (2009) Clinical significance of Smac/DIABLO expression in colorectal cancer. Oncol Rep 21(2): 351-355
10. Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, Findlay BP, Pitot HC, Alberts SR (2004) A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22(1): 23-30 (Pubitemid 41095110)
11. Gourdier I, Del Rio M, Crabbé L, Candeil L, Copois V, Ychou M, Auffray C, Martineau P, Mechti N, Pommier Y, Pau B (2002) Drug specific resistance to oxaliplatin is associated with apoptosis defect in a cellular model of colon carcinoma. FEBS Lett 529(2-3): 232-236
12. Grau E, Martinez F, Orellana C, Canete A, Yañez Y, Oltra S, Noguera R, Hernandez M, Bermúdez JD, Castel V (2011) Hypermethylation of apoptotic genes as independent prognostic factor in neuroblastoma disease. Mol Carcinog 50(3): 153-162
13. Gray R, Barnwell J, McConkey C, Hills RK, Williams NS, Kerr DJ (2007) Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet 370(9604): 2020-2029
14. Gu LQ, Li FY, Zhao L, Liu Y, Chu Q, Zang XX, Liu JM, Ning G, Zhao YJ (2010) Association of XIAP and P27 receptor expression with lymph node metastasis in papillary thyroid carcinoma. Endocrine 38(2): 276-282
15. Harvey JM, Clark GM, Osborne CK, Allred DC (1999) Estrogen Receptor Status by Immunohistochemistry Is Superior to the Ligand-Binding Assay for Predicting Response to Adjuvant Endocrine Therapy in Breast Cancer. J Clin Oncol 17(5): 1474-1481 (Pubitemid 29220854)
16. Hector S, Prehn JH (2009) Apoptosis signaling proteins as prognostic biomarkers in colorectal cancer: a review. Biochim Biophys Acta 1795(2): 117-129
17. Huang H, Zhang XF, Zhou HJ, Xue YH, Dong QZ, Ye QH, Qin LX (2010) Expression and prognostic significance of osteopontin and caspase-3 in hepatocellular carcinoma patients after curative resection. Cancer Sci 101(5): 1314-1319
18. Igney FH, Krammer PH (2002) Death and anti-death: tumour resistance to apoptosis. Nat Rev Cancer 2(4): 277-288 (Pubitemid 37328781)
19. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA: A Cancer J Clin 61(2): 69-90
20. Johnstone RW, Ruefli AA, Lowe SW (2002) Apoptosis: a link between cancer genetics and chemotherapy. Cell 108(2): 153-164 (Pubitemid 34161136)
21. Kaufmann SH, Earnshaw WC (2000) Induction of apoptosis by cancer chemotherapy. Exp Cell Res 256(1): 42-49 (Pubitemid 30211165)
22. Kluger HM, McCarthy MM, Alvero AB, Sznol M, Ariyan S, Camp RL Rimm DL, Mor G (2007) The X-linked inhibitor of apoptosis protein (XIAP) is up-regulated in metastatic melanoma, and XIAP cleavage by Phenoxodiol is associated with Carboplatin sensitization. J Transl Med 5: 6
23. Krajewska M, Kim H, Kim C, Kang H, Welsh K, Matsuzawa S-i Tsukamoto M, Thomas RG, Assa-Munt N, Piao Z, Suzuki KPerucho M, Krajewski S, Reed JC (2005) Analysis of apoptosis protein expression in early-stage colorectal cancer suggests opportunities for new prognostic biomarkers. Clin Cancer Res 11(15): 5451-5461 (Pubitemid 41060821)
24. Li P, Nijhawan D, Budihardjo I, Srinivasula SM, Ahmad M, Alnemri ES, Wang X (1997) cytochrome c and dATP-dependent formation of Apaf-1/Caspase-9 complex initiates an apoptotic protease cascade. Cell 91(4): 479-489 (Pubitemid 27508237)
25. MacFarlane M, Merrison W, Bratton SB, Cohen GM (2002) Proteasomemediated degradation of Smac during apoptosis: XIAP promotes Smac ubiquitination in vitro. J Biol Chem 277(39): 36611-36616
26. McCawley N, Conlon S, Hector S, Cummins RJ, Dicker P, Johnston PG, Kay EW, McNamara DA, Prehn JHM, Concannon CG (2011) Analyzing proteasomal subunit expression reveals Rpt4 as a prognostic marker in stage II colorectal cancer. Int J Cancer; e-pub ahead of print 29 September 2011; doi: 10.1002/ijc.26468
27. McDermott U, Boyd RE, Houston RF, Kee F, McAleer JJ,Millar J, McAdams T, Sloan JM, Moorehead RJ, Wilson RH (2003) A phase III trial of short duration adjuvant chemotherapy with bolus/infusional 5-fluorouracil (FU) and folinic acid (FA) versus surgery alone in dukes' B and C colorectal cancer (CRC). Proc Am Soc Clin Oncol 22: 1363
28. McLornan DP, Barrett HL, Cummins R, McDermott U, McDowell C, Conlon SJ, Coyle VM, Van Schaeybroeck S, Wilson R, Kay EW Longley DB, Johnston PG (2010) Prognostic significance of TRAIL signaling molecules in stage II and III colorectal cancer. Clin Cancer Res 16(13): 3442-3451
29. Paik SS, Jang KS, Song YS, Jang SH, Min KW, Han HX, Na W, Lee KH Choi D, Jang SJ (2007) Reduced expression of Apaf-1 in colorectal adenocarcinoma correlates with tumor progression and aggressive phenotype. Ann Surg Oncol 14(12): 3453-3459 (Pubitemid 350160114)
30. Palmerini F, Devilard E, Jarry A, Birg F, Xerri L (2001) Caspase 7 downregulation as an immunohistochemical marker of colonic carcinoma. Human Pathol 32(5): 461-467 (Pubitemid 32506514)
31. Provencio M, Martin P, Garcia V, Candia A, Sanchez AC, Bellas C (2010) Caspase 3a: new prognostic marker for diffuse large B-cell lymphoma in the rituximab era. Leuk Lymphoma 51(11): 2021-2030
32. Putt KS, Chen GW, Pearson JM, Sandhorst JS, Hoagland MS, Kwon JT, Hwang SK, Jin H, Churchwell MI, Cho MH, Doerge DR, Helferich WG, Hergenrother PJ (2006) Small-molecule activation of procaspase-3 to caspase-3 as a personalized anticancer strategy. Nat Chem Biol 2(10): 543-550 (Pubitemid 44413237)
33. Shi YH, Ding WX, Zhou J, He JY, Xu Y, Gambotto AA, Rabinowich H, Fan J, Yin XM (2008) Expression of X-linked inhibitor-of-apoptosis protein in hepatocellular carcinoma promotes metastasis and tumor recurrence. Hepatology 48(2): 497-507
34. Sinicrope FA, Rego RL, Foster NR, Thibodeau SN, Alberts SR, Windschitl HE, Sargent DJ (2008) Proapoptotic Bad and Bid protein expression predict survival in stages II and III colon cancers. Clin Cancer Res 14(13): 4128-4133
35. Soengas MS, Capodieci P, Polsky D, Mora J, Esteller M, Opitz-Araya X, McCombie R, Herman JG, Gerald WL, Lazebnik YA, Cordon-Cardo C, Lowe SW (2001) Inactivation of the apoptosis effector Apaf-1 in malignant melanoma. Nature 409(6817): 207-211 (Pubitemid 32144287)
36. Strater J, Herter I, Merkel G, Hinz U, Weitz J, Moller P (2010) Expression and prognostic significance of APAF-1, caspase-8 and caspase-9 in stage II/III colon carcinoma: caspase-8 and caspase-9 is associated with poor prognosis. Int J Cancer 127(4): 873-880
37. Suzuki Y, Nakabayashi Y, Takahashi R (2001) Ubiquitin-protein ligase activity of X-linked inhibitor of apoptosis protein promotes proteasomal degradation of caspase-3 and enhances its anti-apoptotic effect in Fas-induced cell death. Proc Natl Acad Sci 98(15): 8662-8667 (Pubitemid 32678084)
38. Verhagen AM, Ekert PG, Pakusch M, Silke J, Connolly LM, Reid GE, Moritz RL, Simpson RJ, Vaux DL (2000) Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins. Cell 102(1): 43-53
39. Xiang G, Wen X, Wang H, Chen K, Liu H (2009) Expression of X-linked inhibitor of apoptosis protein in human colorectal cancer and its correlation with prognosis. J Surg Oncol 100(8): 708-712
40. Zlobec I, Vuong T, Compton CC (2006) The predictive value of apoptosis protease-activating factor 1 in rectal tumors treated with preoperative, high-dose-rate brachytherapy. Cancer 106(2): 284-286 (Pubitemid 43100435)